Spots Global Cancer Trial Database for Diagnostic and Prognostic Accuracy of Gold Nanoparticles in Salivary Gland Tumours

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Diagnostic and Prognostic Accuracy of Gold Nanoparticles in Salivary Gland Tumours

Official Title: Gold Nanoparticles as Novel Biomarkers for Cancer Stem Cells in Salivary Gland Tumors: A Diagnostic and Prognostic Accuracy Study

Study ID: NCT04907422

Conditions

Carcinoma Ex Pleomorphic Adenoma of Salivary Glands

Pleomorphic Adenoma of Salivary Glands

Interventions

CD24-Gold Nanocomposite expression using Real-time quantitative polymerase chain reaction

non-conjugated CD24 expression using Real-time quantitative polymerase chain reaction

Study Description

Brief Summary: Nano-based diagnostic tool can provide promising highly sensitive, specific biomarker for early detection and treatment of salivary gland tumours compared to non-conjugated biomarkers and in turn improves patient prognosis and outcome.

Detailed Description: Cancer stem cells form a small subset of highly tumorigenic cells within the bulk of the tumours which mainly responsible for initiation, invasion, rapid growth, metastasis and therapeutic resistance in different types of human cancers. Nowadays, nanotechnology has increasing attention in multi-disciplinary research fields. Conjugated gold nanoparticles are widely used as biomarkers and bio-delivery vehicles in the medicine as well as early and advanced cancer detection and treatment. The current work aimed to introduce a novel diagnostic and prognostic approach in early detection of cancer stem cells in salivary gland tumours using gold nanoparticles conjugated to CD24 (CD24-Gold Nanocomposite).